BD Reports FY2026 Revenue Growth of 4.9% and Adjusted EPS of $12.70

What happened

BD reported fiscal 2026 revenue of $19.5 billion, up 4.9% year over year, and adjusted diluted earnings per share of $12.70. Fourth-quarter revenue rose 5.4% to $5.3 billion. BD forecast fiscal 2027 low-single-digit revenue growth and adjusted diluted earnings per share of $13.10 to $13.30.

Confirmed

Global impact / market context

The results show revenue growth alongside higher adjusted earnings per share, while the next-year outlook points to slower, low-single-digit revenue growth. That guidance may shape expectations for sales and earnings, influencing how investors assess BD’s ability to sustain growth after its reported business changes.

Analyst inference

BD also completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters on February 9, 2026. Because BD now reports four continuing-operations segments, reported results and comparisons reflect a changed business structure, complicating direct comparisons with earlier periods.

Confirmed

What to watch

1. Compare fiscal 2027 revenue growth with BD’s low-single-digit forecast as future results arrive; stronger or weaker sales could change expectations for the company’s growth trajectory. Analyst inference
2. Track whether adjusted diluted earnings per share reaches the fiscal 2027 guidance range of $13.10 to $13.30, which would indicate progress against management’s stated outlook. Confirmed
3. Watch how BD reports its four continuing-operations segments after the spin-off and combination with Waters, since changes in segment performance could clarify sources of revenue growth. Analyst inference

Evidence

• Original source link unavailable